Literature DB >> 35083171

Sickle Cell Disease-Induced Pulmonary Hypertension: A Review of Pathophysiology, Management, and Current Literature.

Abu Baker Sheikh1, Adeel Nasrullah2, Erick Daniel Lopez1, Mian Tanveer Ud Din2, Shazib Sagheer3, Ishan Shah1, Nismat Javed4, Rahul Shekhar5.   

Abstract

Sickle cell disease is an inherited hemoglobinopathy leading to the synthesis of hemoglobin S. Hemoglobin S results in the formation of abnormal sickle-shaped erythrocytes that lead to hematologic abnormalities such as hemolytic anemia and increased risks of thrombosis. Another particular problem encountered with the disease is pulmonary hypertension. The objective of this narrative review is to discuss the prevalence, pathophysiology mechanisms, diagnostic techniques, treatment options, and prognostic indicators in the setting of sickle cell disease with pulmonary hypertension. Additionally, the review also highlights other advancements that are being investigated. Considering the significant morbidity, mortality, and prevalence of pulmonary hypertension in patients with sickle cell disease, it is important to account for the aforementioned domains in the future guidelines to provide optimal and individualized care to the high-risk individuals as well as reduce the progression of disease, morbidity, and mortality rates.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Diagnosis; Management; Pathophysiology; Pulmonary hypertension; Sickle cell disease

Year:  2021        PMID: 35083171      PMCID: PMC8740209          DOI: 10.1159/000519101

Source DB:  PubMed          Journal:  Pulse (Basel)        ISSN: 2235-8668


  30 in total

1.  Attenuating a sickle cell crisis with annexin V.

Authors:  James Randall Kennedy
Journal:  Med Hypotheses       Date:  2015-01-30       Impact factor: 1.538

2.  Pulmonary hypertension in sickle cell disease.

Authors:  Margaret M Hayes; Amar Vedamurthy; Gautam George; Raed Dweik; Elizabeth S Klings; Roberto F Machado; Mark T Gladwin; Kevin C Wilson; Carey C Thomson
Journal:  Ann Am Thorac Soc       Date:  2014-11

3.  An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

Authors:  Elizabeth S Klings; Roberto F Machado; Robyn J Barst; Claudia R Morris; Kamal K Mubarak; Victor R Gordeuk; Gregory J Kato; Kenneth I Ataga; J Simon Gibbs; Oswaldo Castro; Erika B Rosenzweig; Namita Sood; Lewis Hsu; Kevin C Wilson; Marilyn J Telen; Laura M Decastro; Lakshmanan Krishnamurti; Martin H Steinberg; David B Badesch; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2014-03-15       Impact factor: 21.405

4.  Reduced peripheral blood superoxide dismutase 2 expression in sickle cell disease.

Authors:  Iakovos Armenis; Vassiliki Kalotychou; Revekka Tzanetea; Ioannis Moyssakis; Dimitra Anastasopoulou; Costas Pantos; Kostas Konstantopoulos; Ioannis Rombos
Journal:  Ann Hematol       Date:  2019-05-16       Impact factor: 3.673

5.  Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study.

Authors:  Mehdi Nouraie; Deepika S Darbari; Sohail Rana; Caterina P Minniti; Oswaldo L Castro; Lori Luchtman-Jones; Craig Sable; Niti Dham; Gregory J Kato; Mark T Gladwin; Gregory Ensing; Manuel Arteta; Andrew Campbell; James G Taylor; Sergei Nekhai; Victor R Gordeuk
Journal:  Am J Hematol       Date:  2020-04-21       Impact factor: 10.047

6.  Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.

Authors:  Caterina P Minniti; Roberto F Machado; Wynona A Coles; Vandana Sachdev; Mark T Gladwin; Gregory J Kato
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

7.  Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease.

Authors:  Christopher J Bean; Sheree L Boulet; Dorothy Ellingsen; Meredith E Pyle; Emily A Barron-Casella; James F Casella; Amanda B Payne; Jennifer Driggers; Heidi A Trau; Genyan Yang; Kimberly Jones; Solomon F Ofori-Acquah; W Craig Hooper; Michael R DeBaun
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

8.  American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.

Authors:  Robert I Liem; Sophie Lanzkron; Thomas D Coates; Laura DeCastro; Ankit A Desai; Kenneth I Ataga; Robyn T Cohen; Johnson Haynes; Ifeyinwa Osunkwo; Jeffrey D Lebensburger; James P Lash; Theodore Wun; Madeleine Verhovsek; Elodie Ontala; Rae Blaylark; Fares Alahdab; Abdulrahman Katabi; Reem A Mustafa
Journal:  Blood Adv       Date:  2019-12-10

9.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.

Authors:  Stella T Chou; Mouaz Alsawas; Ross M Fasano; Joshua J Field; Jeanne E Hendrickson; Jo Howard; Michelle Kameka; Janet L Kwiatkowski; France Pirenne; Patricia A Shi; Sean R Stowell; Swee Lay Thein; Connie M Westhoff; Trisha E Wong; Elie A Akl
Journal:  Blood Adv       Date:  2020-01-28

10.  Automated Red Cell Exchange in the Management of Sickle Cell Disease.

Authors:  Dimitris A Tsitsikas; Saket Badle; Rhys Hall; John Meenan; Oloruntoyin Bello-Sanyaolu; Funmilayo Orebayo; Jibril Abukar; Mohamed Elmi; Afsana Mulla; Shalini Dave; Natasha Lewis; Manisha Sharma; Basabi Chatterjee; Roger J Amos
Journal:  J Clin Med       Date:  2021-02-15       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.